Zadnji put ažurirano :
08/05/2024
Lijek protiv karcinoma   Oxaliplatin  
Injekcija
Stabilizacija rješenja Stabilnost mješavine Stabilizacijski faktor Kompatibilnosti Način davanja lijeka Bibliografija Pdf
   Kemijska struktura  

Nekomercijalni   Nekomercijalni     

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Axiplatin Njemačka
Bendaplatin Njemačka
Bioezulen Brazil
Celdach Peru
Crisapla Čile, Ekvador, Venecuela
Crisatinox Turska
Dabenzol Argentina, Ekvador
Dacplat Argentina
Eloxarin Ekvador
Eloxatin Austrija, Belgija, Brazil, Čile, Egipat, Iran, Italija, Kolumbija, Luksemburg, Malezija, Meksiko, Norveška, Novi Zeland, Peru, Portugal, Rumunjska, S A D, Španjolska, Švedska, Švicarska, Tajland, Turska, Ujedinjeni Arapski Emirati, Velika Britanija, Venecuela
Eloxatine Francuska, Maroko, Švicarska
Entia Kolumbija, Meksiko
Euroxaliplatine Njemačka
Glenoxal Peru
Goxyral Argentina, Ekvador
Kebir Argentina, Peru
Linoxa Turska
Lisix Čile
Metaplatin Argentina
Oliptino Argentina
Onicol Čile, Peru
Oxalibbs Brazil
Oxaliplan Njemačka
Riboxatin Njemačka
Bibliografija   Injekcija   Bibliografija : Oxaliplatin  
Vrsta Publikacija
1662 Časopis Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1950 Časopis Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
2207 Časopis André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E.
Stability of oxaliplatin in infusion bags containing 5% dextrose injection.
Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239 Časopis Wang C, Zhang X, Liu HY.
Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry.
Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253 Časopis Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S.
Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
J Synchrotron Rad 2001 ; 8: 716-718.
2258 Laboratorija Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution.
Ebewe Pharma 2007
2259 Laboratorija Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions.
Ebewe Pharma 2007
2321 Časopis Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R.
Stability of Oxaliplatin Solution.
Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791 Časopis Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J.
Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.
Int J Pharm 2015 ; 479 : 23-27.
2883 Časopis Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F.
Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags.
Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369 Laboratorija Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3413 Časopis Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H.
Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex.
Pharm Res 2004 ; 21, 5: 891-894.
3602 Laboratorija Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3634 Laboratorija Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
Accord Healthcare 2011
3670 Časopis Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3706 Časopis Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B.
Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia.
Farm Hosp 2014 ;38, 3:154-161
4004 Časopis Krämer I, Sarakbi I, Thiesen J, Mainz.
Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln.
Krankenhauspharmazie 2017 ;38,7:334?340.

  Mentions Légales